Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN).
Jae Hee CheonHyun Soo KimDong Soo HanSung Kook KimSung Jae ShinJoo Sung KimByong Duk YeGeun Am SongYoungJa LeeYoungdoe KimYoosun LeeByung Chang Kimnull nullPublished in: Gut and liver (2022)
This study provided evidence that infliximab 5 mg/kg induction and maintenance therapies are efficacious and well-tolerated in patients with moderate-to-severe active intestinal BD. (ClinicalTrials.gov identifier: NCT02505568).